A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer

Anne-Sofie Schrohl Rasmussen; Volkmar Mueller; Ib Jarle Christensen; Klaus Pantel; Christoph Thomssen; Nils Brunner

doi:10.1159/000146863

A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer

Anne-Sofie Schrohl Rasmussen, Volkmar Mueller, Ib Jarle Christensen, Klaus Pantel, Christoph Thomssen, Nils Brunner

Biostatistisk afdeling

10 Citationer (Scopus)

Abstract

OBJECTIVE: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been investigated as a potential tumour marker in breast cancer. Here we investigated the correlation between TIMP-1 in tumour tissue and plasma to evaluate whether TIMP-1 in plasma is actually a surrogate marker for TIMP-1 in primary tumours. Furthermore, we assessed whether increased TIMP-1 levels in plasma could be indicative of tumour progression in patients with advanced breast cancer. METHODS: Tumour tissue and preoperatively collected plasma samples from 96 primary breast cancer patients were included together with plasma samples from 46 patients with advanced disease. TIMP-1 levels were measured by ELISA. RESULTS: TIMP-1 levels in plasma (median 81.5 ng/ml, range 41.9-174.9) and tumour tissue (median 25.4 ng/mg of total protein, range 0-110.2) from primary breast cancer patients were not correlated (r = 0.05, p = 0.6). Plasma levels of TIMP-1 in primary breast cancer patients were significantly lower than levels in patients with advanced disease (median 108.7 ng/ml, range 59.7-560.7; p < 0.0001). CONCLUSIONS: Our findings suggest that TIMP-1 release into the blood might be controlled by an active mechanism. They also point to plasma TIMP-1 as a potential marker for predicting tumour progression and for monitoring tumour burden in metastatic breast cancer patients.

Originalsprog	Engelsk
Tidsskrift	Tumor Biology
Vol/bind	29
Udgave nummer	3
Sider (fra-til)	181-187
Antal sider	7
ISSN	1010-4283
DOI	https://doi.org/10.1159/000146863
Status	Udgivet - 2008

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1159/000146863

Citationsformater

A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer. / Rasmussen, Anne-Sofie Schrohl; Mueller, Volkmar; Christensen, Ib Jarle et al.

I: Tumor Biology, Bind 29, Nr. 3, 2008, s. 181-187.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{8dc09f70c51111dd8ca2000ea68e967b,

title = "A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer",

abstract = "OBJECTIVE: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been investigated as a potential tumour marker in breast cancer. Here we investigated the correlation between TIMP-1 in tumour tissue and plasma to evaluate whether TIMP-1 in plasma is actually a surrogate marker for TIMP-1 in primary tumours. Furthermore, we assessed whether increased TIMP-1 levels in plasma could be indicative of tumour progression in patients with advanced breast cancer. METHODS: Tumour tissue and preoperatively collected plasma samples from 96 primary breast cancer patients were included together with plasma samples from 46 patients with advanced disease. TIMP-1 levels were measured by ELISA. RESULTS: TIMP-1 levels in plasma (median 81.5 ng/ml, range 41.9-174.9) and tumour tissue (median 25.4 ng/mg of total protein, range 0-110.2) from primary breast cancer patients were not correlated (r = 0.05, p = 0.6). Plasma levels of TIMP-1 in primary breast cancer patients were significantly lower than levels in patients with advanced disease (median 108.7 ng/ml, range 59.7-560.7; p < 0.0001). CONCLUSIONS: Our findings suggest that TIMP-1 release into the blood might be controlled by an active mechanism. They also point to plasma TIMP-1 as a potential marker for predicting tumour progression and for monitoring tumour burden in metastatic breast cancer patients.",

author = "Rasmussen, {Anne-Sofie Schrohl} and Volkmar Mueller and Christensen, {Ib Jarle} and Klaus Pantel and Christoph Thomssen and Nils Brunner",

note = "Keywords: Adult; Aged; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Tissue Inhibitor of Metalloproteinase-1; Tumor Markers, Biological",

year = "2008",

doi = "10.1159/000146863",

language = "English",

volume = "29",

pages = "181--187",

journal = "Tumor Biology",

issn = "1010-4283",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer

AU - Rasmussen, Anne-Sofie Schrohl

AU - Mueller, Volkmar

AU - Christensen, Ib Jarle

AU - Pantel, Klaus

AU - Thomssen, Christoph

AU - Brunner, Nils

N1 - Keywords: Adult; Aged; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Tissue Inhibitor of Metalloproteinase-1; Tumor Markers, Biological

PY - 2008

Y1 - 2008

N2 - OBJECTIVE: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been investigated as a potential tumour marker in breast cancer. Here we investigated the correlation between TIMP-1 in tumour tissue and plasma to evaluate whether TIMP-1 in plasma is actually a surrogate marker for TIMP-1 in primary tumours. Furthermore, we assessed whether increased TIMP-1 levels in plasma could be indicative of tumour progression in patients with advanced breast cancer. METHODS: Tumour tissue and preoperatively collected plasma samples from 96 primary breast cancer patients were included together with plasma samples from 46 patients with advanced disease. TIMP-1 levels were measured by ELISA. RESULTS: TIMP-1 levels in plasma (median 81.5 ng/ml, range 41.9-174.9) and tumour tissue (median 25.4 ng/mg of total protein, range 0-110.2) from primary breast cancer patients were not correlated (r = 0.05, p = 0.6). Plasma levels of TIMP-1 in primary breast cancer patients were significantly lower than levels in patients with advanced disease (median 108.7 ng/ml, range 59.7-560.7; p < 0.0001). CONCLUSIONS: Our findings suggest that TIMP-1 release into the blood might be controlled by an active mechanism. They also point to plasma TIMP-1 as a potential marker for predicting tumour progression and for monitoring tumour burden in metastatic breast cancer patients.

AB - OBJECTIVE: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been investigated as a potential tumour marker in breast cancer. Here we investigated the correlation between TIMP-1 in tumour tissue and plasma to evaluate whether TIMP-1 in plasma is actually a surrogate marker for TIMP-1 in primary tumours. Furthermore, we assessed whether increased TIMP-1 levels in plasma could be indicative of tumour progression in patients with advanced breast cancer. METHODS: Tumour tissue and preoperatively collected plasma samples from 96 primary breast cancer patients were included together with plasma samples from 46 patients with advanced disease. TIMP-1 levels were measured by ELISA. RESULTS: TIMP-1 levels in plasma (median 81.5 ng/ml, range 41.9-174.9) and tumour tissue (median 25.4 ng/mg of total protein, range 0-110.2) from primary breast cancer patients were not correlated (r = 0.05, p = 0.6). Plasma levels of TIMP-1 in primary breast cancer patients were significantly lower than levels in patients with advanced disease (median 108.7 ng/ml, range 59.7-560.7; p < 0.0001). CONCLUSIONS: Our findings suggest that TIMP-1 release into the blood might be controlled by an active mechanism. They also point to plasma TIMP-1 as a potential marker for predicting tumour progression and for monitoring tumour burden in metastatic breast cancer patients.

U2 - 10.1159/000146863

DO - 10.1159/000146863

M3 - Journal article

C2 - 18645261

SN - 1010-4283

VL - 29

SP - 181

EP - 187

JO - Tumor Biology

JF - Tumor Biology

IS - 3

ER -

A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater